BiotechTube

Nabiximols + Placebo

Phase 2/3Withdrawn
0 watching 0 views this week📈 Rising
62
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Post-Traumatic Stress Disorder

Conditions

Post-Traumatic Stress Disorder

Trial Timeline

Feb 1, 2021 → Mar 1, 2023

NCT ID
NCT04592159

About Nabiximols + Placebo

Nabiximols + Placebo is a phase 2/3 stage product being developed by Jazz Pharmaceuticals for Post-Traumatic Stress Disorder. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04592159. Target conditions include Post-Traumatic Stress Disorder.

Hype Score Breakdown

Clinical
22
Activity
15
Company
7
Novelty
7
Community
8

Clinical Trials (5)

NCT IDPhaseStatus
NCT05974293Phase 2Withdrawn
NCT04984278Phase 3Terminated
NCT04592159Phase 2/3Withdrawn
NCT04657666Phase 3Completed
NCT04203498Phase 3Terminated

Competing Products

16 competing products in Post-Traumatic Stress Disorder

See all competitors
ProductCompanyStageHype Score
Galcanezumab-GnlmEli LillyApproved
85
Quetiapine Fumarate + quetiapine fumarate placeboAstraZenecaPhase 3
77
Rizatriptan + PlaceboMerckPre-clinical
23
AMG 334NovartisPhase 2
52
Balovaptan + PlaceboRochePhase 2
52
ErenumabAmgenPhase 2
51
PF-04457845 + PlaceboPfizerPhase 2
51
Zoloft (Sertraline)PfizerPhase 3
76
Levetiracetam + PlaceboUCBPhase 3
74
levetiracetam + Placebo + LevetriracetamUCBPhase 2/3
62
Placebo + BrexpiprazoleLundbeckPhase 3
74
Brexpiprazole + Sertraline + Brexpiprazole Matching Placebo + Sertraline Matching PlaceboLundbeckPhase 2
49
AbobotulinumtoxinA + Normal salineIpsenApproved
82
60 mg PRAX-114 or 40 mg PRAX-114 + Placebo + 40 mg PRAX-114Praxis Precision MedicinesPhase 2
49
MDMANautilus BiotechnologyPhase 2
44
Tramadol + PlaceboBrain BiotechApproved
77

Other Products from Jazz Pharmaceuticals

Sativex + PlaceboApproved
82
Sodium OxybateApproved
82
JZP258Approved
82
Solriamfetol + PlaceboApproved
82
Placebo + Sodium OxybateApproved
82